共 33 条
- [1] Poklepovic AS(2020)Considering adjuvant therapy for stage II melanoma Cancer 126 1166-1174
- [2] Luke JJ(2022)Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer Version 8 validated in two independent cohorts: implications for adjuvant treatment J. Clin. Oncol. 40 3741-3749
- [3] Garbe C(2017)Melanoma staging: evidence-based changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual CA Cancer J. Clin. 67 472-492
- [4] Gershenwald JE(2020)Prognosis of patients with stage III melanoma according to American Joint Committee on Cancer Version 8: a reassessment on the basis of 3 independent stage III melanoma cohorts J. Clin. Oncol. 38 2543-2551
- [5] Garbe C(2015)Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial Lancet Oncol. 16 522-530
- [6] Eggermont AMM(2017)Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma N. Engl. J. Med. 377 1824-1835
- [7] Weber J(2023)Adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238 Clin. Cancer Res. 29 3352-3361
- [8] Larkin J(2018)Adjuvant pembrolizumab versus placebo in resected stage III melanoma N. Engl. J. Med. 378 1789-1801
- [9] Eggermont AMM(2021)Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomized, controlled, phase 3 trial Lancet Oncol. 22 643-654
- [10] Eggermont AMM(2022)Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial Lancet 399 1718-1729